Biomarkers development for early detection of cancer: Reducing the burden of cancer in the ageing society

Open access


The ageing process in the European society will become one of the key driving forces of change over the next decades. The specific demands of older generations constitute a key market of the future, and the pressure to improve and expand health services increases, especially as far as chronic diseases, such as cancer. Availability of cost effective cancer early detection protocols, based on predictive biomarkers, will improve patients management reducing consequently the high costs associated to treating patients when the disease is at an advanced stage.

1. American Cancer Society, Global Cancer Facts & Figures 3rd Edition. 2015, American Cancer Society: Atlanta.

2. National Cancer Institute. Probability of Developing or Dying of Cancer. 2015 [cited 2016] ; Available from:

3. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncology. 2012. 13: 790-801.

4. Vollmers HP, Brandlein S. Natural antibodies and cancer. Journal of Autoimmunity. 2007. 29(4): 295-302.

5. Beneduce L, Prayer-Galletti T, Marcello Grimani Giustinian A, Gallotta A, Betto G, Pagano F, Fassina G. Detection of prostate specific antigen coupled to immunoglobulin M In prostate cancer patients. Cancer Detection and Prevention. 2007. 31: 402-407.

6. Castaldi F, Marino M, Beneduce L, Belluco C, De Marchi F, Mammano E, Nitti D, Lise M, Fassina G. Detection of circulating CEA-IgM complexes in early stage colorectal cancer. International Journal of Biological Markers. 2005. 20(4): 204-208.

7. Beneduce L, Castaldi F, Marino M, Quarta S, Ruvoletto M, Benvegnù L, Calabrese F, Gatta A, Pontisso P, Fassina G. Squamous cell carcinoma antigen-Immunoglobulin M complexes as novel biomarkers for hepatocellular carcinoma. Cancer. 2005. 103: 2558-2565.

8. Beneduce L, Castaldi F, Marino M, Tono N, Gatta A, Pontisso P, Fassina G. Improvement of liver cancer detection with simultaneous assessment of circulating levels of free alpha-fetoprotein (AFP) and AFP-IgM complexes. International Journal of Biological Markers. 2004. 19: 155-159.

9. Beneduce L, Pesce G, Gallotta A, Zampieri F, Biasiolo A, Tono N, Boscato N, Gatta A, Pontisso P, Fassina G. Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma. European Journal of Clinical Investigation. 2008. 38: 571-577.

10. Martini A, Gallotta A, Pontisso P, Fassina G. Clinical applications of squamous cell carcinoma antigen_immunoglobulins M to monitor chronic hepatitis C. World Journal of Hepatology. 2015. 7(29): 2913-2919.

11. Biggins SW, Bambha KM, Terrault NA, Inadomi J, Shiboski S, Dodge JL, Gralla J, Rosen HR, Roberts JP. Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver Transplantation. 2012. 18: 1471-1478.

12. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010. 138: 513-521.

13. World Health Organization, World report on aging and health. 2015.

14. EASL-EORTC. Clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology. 2012. 56: 908-943.

15. Bruix J,Sherman M. Management of hepatocellular carcinoma: an update.Hepatology. 2011. 53(3): 1020-1022.

16. Biasiolo A, Chemello L, Quarta S, Cavalletto L, Bortolotti F, Caberlotto C, Beneduce L, Bernardinello E, Tono N, Fassina G, Gatta A, Pontisso P. Monitoring SCCA-IgM complexes in serum predicts liver disease progression in patients with chronic hepatitis. Journal of Viral Hepatitis. 2008. 15: 246-249.

17. Pontisso P,Quarta S, Caberlotto C, Beneduce L, Marino M, Bernardinello E, Tono N, Fassina G, Cavalletto L, Gatta A, Chemello L. Progressive increse of SCCA-IgM immune complexes in cirrhotic patients is associated with development of hepatocellular carcinoma. International Journal of Cancer. 2006. 119: 735-740.

18. Biasiolo A, Trotta E, Fasolato S, Ruvoletto M, Martini A, Gallotta A, Fassina G, Angeli P, Gatta A, Pontisso P. Squamous cell carcinoma antigen-IgM is associated with hepatocellular carcinoma in patients with cirrhosis: A prospective study.Digestive Liver Disease. 2016. 48(2): 197-202.

19. Buccione D, Fatti G, Gallotta A, Loggi E, Di Donato R, Testa L, Saitta C, Santi V, Di Micoli A, Erroi V, Frigerio M, Fazio V, Picciotto A, Biasiolo A, Degos F, Pontisso P, Raimondo G, Trevisani F. Serum SCCA-IgM as a predictor of hepatocellular carcinoma in patients with cirrhosis. Open Journal of Gastroenterology. 2012. 2: 56-61.

20. Morisco F,Guarino M, Di Costanzo GG, Gallotta A, Fassina G, Tortora R, Tuccillo C, Granata R, Loperto I, Auriemma F, Caporaso N. Circulating SCCA-IgM complex is a useful biomarker to predict the outcome of therapy in HCC patients. Journal of Hepatology. 2015. 62(S450).

21. Giannelli G, Fransvea E, Trerotoli P, Beaugrand M, Marinosci F, Lupo L, Nkontchou G, Dentico P, Antonaci S. Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients. Clinica Chimica Acta. 2007. 383: 147-152.

22. Crescenzi M, Tessari A, Biasiolo A, Padoan A, Gallotta A, Fassina G, Panciatichi C, Rossetto O, Pontisso P, Basso D, Plebani M. Analytical Validation of a biochip prototype for integrated analysis of AFPIgM and SCCA-IgM serum biomarkers in patients with liver cirrhosis and hepatocellular carcinoma.Analytical Methods. 2015(2): 626-637.

23. Gil-Gómez A, Ampuero J, Gallego-Durán R, Fassina G, Pontisso P, Romero-Gomez M. SCCA-IgM helps to identify patients at risk of long-term hepatocellular carcinoma.Hepatology. 2016. 64(S1): 656A.

24. Regione Veneto. Tariffario delle Prestazioni Specialistiche Ambulatoriali.

25. AIRTUM-AIOM, I numeri del cancro in Italia. 2016.

26. Giannini EG,Cucchetti A, Erroi V, Garuti F, Odaldi F, Trevisani F. Surveillance for early diagnosis of hepatocellular carcinoma: how best to do it? World Journal of Gastroenterology. 2013. 19(47): 8808-8821.

27. Thompson Coon J,Rogers G, Hewson P, Wright D, Anderson R, Jackson S, Ryder S, Cramp M, Stein K. Surveillance of cirrhosis for hepatocellular carcinoma: a cost-utility analysis. British Journal of Cancer. 2008. 98: 1166-1175.

Journal Information


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 200 200 14
PDF Downloads 80 80 5